Bayer Q2 2026 Media Update

Bayer operationally on track, decisive progress on strategic priorities

Group sales increase 2.2 percent (Fx & portfolio adj.) to 10.872 billion euros
EBITDA before special items rises 1.9 percent to 2.144 billion euros
EBITDA before special items rises 1.9 percent to 2.144 billion euros
Pharmaceuticals sales at prior-year level, earnings down
Consumer Health registers slightly higher sales and lower earnings
Core earnings per share at 0.95 euros, 16.7 percent below prior year
Net income improves to 219 million euros
Free cash flow declines to minus 371 million euros, partly due to settlement payments
Net financial debt at 33.647 billion euros
Currency-adjusted Group outlook confirmed, with net financial debt to be lower than originally projected
Company focused on advancing its strategic priorities

Strategy and Financial Update

Bayer CEO Bill Anderson shares an overview of where Bayer stands at the half-year mark – in 90 seconds.

Recording of the Media Update

Watch the full Video Webcast

CFO of Bayer AG

CEO of Bayer AG